CTS-1027

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C19H20ClNO6S
Molecular Weight	425.883
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

ONC(=O)C3(CS(=O)(=O)C1=CC=C(OC2=CC=C(Cl)C=C2)C=C1)CCOCC3

InChI

InChIKey=ROSNVSQTEGHUKU-UHFFFAOYSA-N

InChI=1S/C19H20ClNO6S/c20-14-1-3-15(4-2-14)27-16-5-7-17(8-6-16)28(24,25)13-19(18(22)21-23)9-11-26-12-10-19/h1-8,23H,9-13H2,(H,21,22)

HIDE SMILES / InChI

Molecular Formula	C19H20ClNO6S
Molecular Weight	425.883
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://clinicaltrials.gov/ct2/show/results/NCT01051921 | https://www.prnewswire.com/news-releases/conatus-pharmaceuticals-terminates-phase-2-clinical-trial-of-cts-1027-132545253.html | https://www.ncbi.nlm.nih.gov/pubmed/25890041

CTS-1027 (Ro-1130830) is a hydroxamic acid matrix metalloprotease (MMP) inhibitor. CTS-1027 was originally designed as a strong inhibitor of MMP-2, -3, -8, -9, -12, -13 and -14, without inhibiting MMP-1 and MMP-7. CTS-1027 was proved to be safe in clinical trials for osteoarthritis conducted by Roche. CTS-1027 was then licensed from Roche to Conatus Pharmaceuticals and was investigated as a protector from liver fibrosis in hepatitis C virus patients. The development of the drug was discontinued due to laboratory abnormalities and adverse events in a subset of clinical trial participants.

Approval Year

Targets

Primary Target	Pharmacology	Potency
Matrix metalloproteinase-2 13 Target ID: CHEMBL333 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10669559	Inhibitor 8504	0.22 nM [Ki]
Matrix metalloproteinase 3 13 Target ID: CHEMBL283 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10669559	Inhibitor 8504	9.3 nM [Ki]
Matrix metalloproteinase 9 20 Target ID: CHEMBL321 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10669559	Inhibitor 8504	0.58 nM [Ki]
Matrix metalloproteinase 13 8 Target ID: CHEMBL280 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10669559	Inhibitor 8504	0.52 nM [Ki]

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:07:47 GMT 2025` Edited by `admin` on `Mon Mar 31 18:07:47 GMT 2025`
Record UNII	2QD3F58224
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

RO-1130830

Preferred Name

English

CTS-1027

Common Name

English

4-(4-(4-CHLORO-PHENOXY)-BENZENESULFONYLMETHYL)-TETRAHYDRO-PYRAN-4-CARBOXYLIC ACID HYDROXYAMIDE

Systematic Name

English

4-(4-(4-CHLORO-PHENOXY)-BENZENESULFONYLMETHYL )-TETRAHYDRO-PYRAN-4-CARBOXYLIC ACID HYDROXYAMIDE

Systematic Name

English

RS-130830

Code

English

2H-PYRAN-4-CARBOXAMIDE, 4-(((4-(4-CHLOROPHENOXY)PHENYL)SULFONYL)METHYL)TETRAHYDRO-N-HYDROXY-

Systematic Name

English

4-(((4-(4-CHLOROPHENOXY)PHENYL)SULFONYL)-METHYL) TETRAHYDRO-N-HYDROXY-2H-PYRAN-4-CARBOXAMIDE

Systematic Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

258308